All News

A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.

Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.

A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.

Findings highlight an AI-based machine-learning approach designed to work around incomplete diagnostic labeling in Alzheimer disease using routine clinical data.

Your daily dose of the clinical news you may have missed.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

WHO experts weighed decades of high-quality studies against flawed analyses, finding consistent evidence that current vaccines pose no autism-related risk.

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.